4 reports

  • 10.12 CUREVAC

At the 2012 Society for Immunotherapy Annual Meeting, results from a Phase ## study of CDX-## were presented.

  • Cancer Immunotherapy
  • Immunotherapy
  • Therapy
  • Vaccine
  • CureVac GmbH

THE RESULTS HAVE SHOWN THAT IMT-## IMMUNOTHERAPY PROVIDES SURVIVAL ADVANTAGE IN BACTEREMIA AND SEPSIS IN NEUTROPENIC ANIMALS.

  • Immunotherapy
  • Infectious Disease
  • Pathology
  • Vaccine
  • CureVac GmbH

THE RESULTS HAVE SHOWN THAT IMT-## IMMUNOTHERAPY PROVIDES SURVIVAL ADVANTAGE IN BACTEREMIA AND SEPSIS IN NEUTROPENIC ANIMALS.

  • Immunotherapy
  • Infectious Disease
  • Therapy
  • Vaccine
  • CureVac GmbH

The drug candidate is a self-adjuvanted, sequence-optimized, chemically unmodified mRNA immunotherapy targeting four antigens prostate-specific antigen (PSA), prostate-specific membrane antigen (PSMA), prostate stem cell antigen (PSCA), and six-transmembrane epithelial antigen of the prosta

  • Immunotherapy
  • Research And Development
  • Vaccine
  • Company Operations
  • CureVac GmbH